Clinical trial
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy…
NCT00433589 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00433589 |
|---|---|
| Title | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes |
| Official title | MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive… |
| Acronym | MINDACT |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Collaborators | Agendia Industry Breast International Group Roche Pharma AG Novartis Sanofi |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | anthracycline-based, docetaxel and capecitabine, tamoxifen, Letrozole |
| Enrollment | 6,600 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2020 |
| Completion | Mar 1, 2020 |
| First posted | Feb 12, 2007 |
| Last update posted | Nov 17, 2022 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: